NIH Workshop to Accelerate Therapeutic Innovation by Optimizing Kidney Precision Medicine Clinical Trials

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) sponsored a scientific workshop in 2024, titled "Preparing for Kidney Precision Medicine Clinical Trials." The purpose of the workshop was to gain a better understanding of the therapeutic journey of patients with kidney disease and define candidate indicators for precision medicine strategies, targets, and trial readiness. Workshop participants were tasked with identifying best practices, opportunities and barriers to kidney precision medicine clinical trials, with a shared goal to optimize the design and conduct of these trials. The patient perspective served as a foundation for the meeting. Trial design should be flexible, dynamic, responsive to transitions in patient care and minimize fragmentation of care. The value of understanding mechanisms and defining endophenotypes and targets to facilitate new therapeutic approaches was discussed with examples presented for acute and chronic kidney diseases. The importance of biomarkers for diagnosis and evaluation of therapeutic response was emphasized. Laboratory and assay considerations for precision medicine trials were discussed with examples of successful large precision medicine trials supported by laboratory networks presented. There was discussion of the barriers to precision trials in nephrology, including suboptimal patient engagement, precision trial expertise, infrastructure and financial resources. Engagement in demonstration projects to test the ability of various approaches to expedite the right treatment to the right patient was highlighted. Of utmost importance is the better design of clinical trials which consider differences in genetics and status of disease mechanisms to validate individual patient-focused innovative and effective precision therapeutic approaches.

Authors

Institutions

Publication Details

Journal
Clinical Journal of the American Society of Nephrology
Published
2026-02-17
DOI
https://doi.org/10.2215/cjn.0000001031
Primary Topic
Chronic Kidney Disease and Diabetes
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

NIH Workshop to Accelerate Therapeutic Innovation by Optimizing Kidney Precision Medicine Clinical Trials

Paul T. Conway, Mark David Lim, Melanie S. Joy, Glenn M Chertow et al.
Clinical Journal of the American Society of Nephrology
Chronic Kidney Disease and Diabetes
article

NIH Workshop to Accelerate Therapeutic Innovation by Optimizing Kidney Precision Medicine Clinical Trials

Paul T. Conway, Mark David Lim, Melanie S. Joy, Glenn M Chertow, Joseph V. Bonventre, Rasheed A. Gbadegesin, Matthias Kretzler, On behalf of the Precision Medicine Workshop Speakers and Moderators, Kathleen D. Liu
article en

Abstract

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) sponsored a scientific workshop in 2024, titled "Preparing for Kidney Precision Medicine Clinical Trials." The purpose of the workshop was to gain a better understanding of the therapeutic journey of patients with kidney disease and define candidate indicators for precision medicine strategies, targets, and trial readiness. Workshop participants were tasked with identifying best practices, opportunities and barriers to kidney precision medicine clinical trials, with a shared goal to optimize the design and conduct of these trials. The patient perspective served as a foundation for the meeting. Trial design should be flexible, dynamic, responsive to transitions in patient care and minimize fragmentation of care. The value of understanding mechanisms and defining endophenotypes and targets to facilitate new therapeutic approaches was discussed with examples presented for acute and chronic kidney diseases. The importance of biomarkers for diagnosis and evaluation of therapeutic response was emphasized. Laboratory and assay considerations for precision medicine trials were discussed with examples of successful large precision medicine trials supported by laboratory networks presented. There was discussion of the barriers to precision trials in nephrology, including suboptimal patient engagement, precision trial expertise, infrastructure and financial resources. Engagement in demonstration projects to test the ability of various approaches to expedite the right treatment to the right patient was highlighted. Of utmost importance is the better design of clinical trials which consider differences in genetics and status of disease mechanisms to validate individual patient-focused innovative and effective precision therapeutic approaches.

Clinical Journal of the American Society of Nephrology
Brigham and Women's Hospital (US), Duke University (US), University of California, San Francisco (US), University of Michigan (US), American Society of Nephrology (US), Michigan Medicine (US), American Association of Kidney Patients (US), University of Colorado Denver (US), Stanford University (US)
Industry, innovation and infrastructure
Openalex Percentile: Top 58%
Chronic Kidney Disease and Diabetes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.